ctDNA Assay in Patients With Resectable Pancreatic Cancer
Recruiting now
Conditions studied: Pancreas Cancer
In brief
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Key facts
- Study ID
- NCT05052671
- Run by
- University of Oklahoma
- People needed
- 50
- Starts
- 2022-05-25
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-03-05
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Newly diagnosed exocrine pancreatic cancer with either pathology or radiology imaging suggestive of adenocarcinoma
- Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines
- ≥ 18 years old at the time of informed consent
- ECOG Performance Status 0 or 1
- Patients who are candidates for neoadjuvant chemo/chemoradiotherapy or upfront surgery are eligible for the study.
- Ability to provide written informed consent and HIPAA authorization
- Patients must have a life expectancy of at least 6 months
You may not qualify if…
- Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies
- Positive pregnancy test, pregnant, or breastfeeding
- Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
- Locally advanced or metastatic disease
Where it is running
- University of Oklahoma — Oklahoma City, Oklahoma, United States (enrolling)
- Stephenson Cancer Center- Tulsa — Tulsa, Oklahoma, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.